Under the agreement, Mankind Pharma will have the exclusive rights to register, import, market, sell, and distribute Sintilimab in India. Credit: Piotr Swat/Shutterstock.

Mankind Pharma has entered into a partnership with Innovent Biologics for exclusively licensing and commercialising Sintilimab, an immunotherapy for cancer treatment in India.

This strategic move is aimed at addressing significant challenges in cancer care and enhance patient access to new therapeutic options.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Sintilimab, known as TYVYT (sintilimab injectable) in China, was developed through a collaboration between Eli Lilly and Innovent.

Currently, the asset is not approved in India, IIFL Capital reported.

Earlier next year, Mankind Pharma plans to seek regulatory approval in India and complete all regulatory processes, including the conduct of a Phase III study in the country.

The study will commence once the company receives regulatory approval to conduct such studies.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Under the agreement, Mankind Pharma will have the exclusive rights to register, import, market, sell, and distribute Sintilimab in India.

Innovent will oversee the manufacturing and supply of the product to ensure steady availability and adherence to quality standards.

Innovent Biologics chief business officer Samuel Zhang said: “The company is committed to advancing patient care in India by making cutting-edge treatments more accessible and affordable.”

In July 2024, Mankind Pharma entered into a definitive agreement to acquire 100% of Bharat Serums and Vaccines (BSV) from private equity investor Advent International for an enterprise value of approximately Rs136.3bn ($1.59bn).

Bharat Serums, a biopharmaceutical company founded in 1971, has a research and development centre in the Indian city of Mumbai with over 100 scientists.

It operates in more than 70 countries, with subsidiaries in Germany, the Philippines, and the US.